Loading…
Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study)
Aim Lutetium‐177 (Lu‐177) prostate‐specific membrane antigen radioligand therapy (PSMA‐RLT) is a promising therapy for metastatic castration‐resistant prostate cancer (mCRPC), but there is limited data of its efficacy and safety in Asian population. We aim to explore the clinical outcomes of Lu‐177...
Saved in:
Published in: | Asia-Pacific journal of clinical oncology 2024-10, Vol.20 (5), p.572-581 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Aim
Lutetium‐177 (Lu‐177) prostate‐specific membrane antigen radioligand therapy (PSMA‐RLT) is a promising therapy for metastatic castration‐resistant prostate cancer (mCRPC), but there is limited data of its efficacy and safety in Asian population. We aim to explore the clinical outcomes of Lu‐177 PSMA‐RLT in this population.
Methods
We evaluated 84 patients with progressive mCRPC receiving Lu‐177 PSMA‐RLT between 9 May 2018 and 21 February 2022. Lu‐177‐PSMA‐I&T was administered at 6–8‐week intervals. Primary end point was overall survival (OS), and secondary end points included prostate‐specific antigen (PSA) progression‐free survival (PFS), PSA response rate, clinical response, toxicity assessment, and prognostic indicators.
Results
The median OS and PSA PFS were 12.2 and 5.2 months, respectively. PSA decline of ≥50% was observed in 51.8% of patients. Patients achieving PSA response had longer median OS (15.0 vs. 9.5 months, p = .03) and PSA PFS (6.5 vs. 2.9 months, p |
---|---|
ISSN: | 1743-7555 1743-7563 1743-7563 |
DOI: | 10.1111/ajco.13944 |